Composition for treating pharyngitis

Abstract

The invention firstly discloses the composition for treating sphagitis. The composition is prepared from 30-40% of dendrobium officinale and 30-40% of fructus phyllanthi. And the balance of honey. Preparing the dendrobium officinale into superfine powder, preparing the fructus phyllanthi into superfine powder, and uniformly mixing the superfine powder with the honey to obtain the composition. The composition is mixed with a pharmaceutically common excipient to obtain the medicine for treating sphagitis. The medicine comprises but is not limited to tablets, capsules, pills and liquid preparations. The invention develops a novel natural formula preparation, and experiments prove that the preparation can effectively prevent and treat pharyngitis.

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and particularly to a traditional Chinese medicine composition for treating pharyngolaryngitis. Background Art

[0002] Pharyngolaryngitis is an acute and chronic inflammation of the pharyngeal mucosa, submucosa and lymphoid tissue, generally caused by bacteria or viruses, characterized by a long course, easy recurrence and difficulty in cure. The common clinical symptoms of this disease include discomfort in the throat, foreign body sensation, burning sensation, dryness sensation. The common physical signs include congestion of the pharyngeal wall mucosa, showing dark red color, and scattered raised small particles or patches like beads can be seen on the posterior pharyngeal wall, with an expanded vascular network around them, and sometimes mucus or purulent secretions are attached to the surface.

[0003] At present, there are two treatment options for treating pharyngolaryngitis. One is anti-inflammatory drugs of Western medicine, which directly and strongly kill bacteria and viruses, but this method is likely to kill normal bacteria in the human body and is also prone to side effects such as drug resistance. The other is traditional Chinese medicines such as mint, honeysuckle, and boat-fruited sterculia with the effects of relieving sore throat and moistening the lungs, but these traditional Chinese medicines can usually only relieve the discomfort in the throat and cannot cure the pharyngeal inflammation.

[0004] Based on the above analysis, a composition that can effectively improve the mucus and purulent secretions in the affected area, shorten the treatment cycle, and eliminate inflammation at the same time is urgently needed in the current industry. Summary of the Invention

[0005] In view of the above deficiencies, the present invention proposes a composition for treating pharyngitis, which can not only solve the anti-inflammatory side effects of traditional Western medicine treatment, but also effectively cure the symptoms of pharyngolaryngitis, relieve and eliminate inflammation.

[0006] In order to achieve the above technical effects, the present invention adopts the following technical means:

[0007] The present invention first discloses a composition for treating pharyngolaryngitis, comprising:

[0008] 30-40% dendrobium officinale;

[0009] 30-40% phyllanthus emblica; and

[0010] the balance honey.

[0011] Further, the composition comprises:

[0012] 35% dendrobium officinale;

[0013] 35% phyllanthus emblica; and

[0014] the balance honey.

[0015] Further, the Dendrobium officinale is freeze-dried and then ultrafinely pulverized to form Dendrobium officinale ultrafine powder with a particle size of 10 ± 5 μm.

[0016] Further, the Phyllanthus emblica is pitted, freeze-dried, and then ultrafinely pulverized into Phyllanthus emblica ultrafine powder with a particle size of 10 ± 5 μm.

[0017] The present invention also discloses a preparation method of the above composition for treating pharyngitis, including:

[0018] Mix the Dendrobium officinale ultrafine powder, Phyllanthus emblica ultrafine powder, and honey evenly to obtain the composition.

[0019] A drug for treating pharyngitis includes:

[0020] Mix any of the above compositions with pharmaceutically common excipients to obtain a drug for treating pharyngitis.

[0021] Further, the drug includes but is not limited to:

[0022] Tablets, capsules, pills, liquid preparations.

[0023] The present invention also discloses the application of any of the above compositions in treating pharyngitis.

[0024] The present invention also discloses the application of the above drug in treating pharyngitis.

[0025] The beneficial effects of the present invention are as follows:

[0026] (1) A new type of natural formula preparation is developed;

[0027] (2) The preparation can effectively prevent and treat pharyngitis. Description of the Drawings

[0028] Figure 1 It is a flow chart of the pharyngitis modeling process and anti-inflammatory test for mice in the present invention.

[0029] Figure 2 It is a statistical chart for verifying the pharyngitis treatment effect of the formula preparation using a mouse pharyngitis model in the present invention.

[0030] Figure 3 It is a legend of pharyngeal sections of mice in different groups in the present invention. Detailed Embodiments

[0031] The present invention will be further described below with reference to the embodiments.

[0032] A composition for treating pharyngolaryngitis provided by the present invention comprises: 30-40% of Dendrobium officinale; 30-40% of Phyllanthus emblica; and the balance of honey. Among them, Dendrobium officinale is freeze-dried and then ultrafinely pulverized to form Dendrobium officinale ultrafine powder with a particle size of 10±5μm. Phyllanthus emblica is pitted and then freeze-dried, and then ultrafinely pulverized to form ultrafine powder with a particle size of 10±5μm. The present invention will be further described in detail by way of examples below.

[0033] Example 1

[0034] A composition for treating pharyngolaryngitis comprises:

[0035] 30% of Dendrobium officinale;

[0036] 30% of Phyllanthus emblica; and

[0037] the balance of honey.

[0038] Example 2

[0039] 40% of Dendrobium officinale;

[0040] 40% of Phyllanthus emblica; and

[0041] the balance of honey.

[0042] Example 3

[0043] 35% of Dendrobium officinale;

[0044] 35% of Phyllanthus emblica; and

[0045] the balance of honey.

[0046] Test Example 1

[0047] In vitro anti-inflammatory effect test

[0048] The experiment on inhibiting nitric oxide production activity of the aqueous solution of the above formula preparation at the cellular level and its results.

[0049] Test method

[0050] RPMI 1640 medium containing 10% FBS was placed in a 96-well plate, and mouse monocyte RAW264.7 macrophages were added. The cells were cultured in a humidified condition at 37°C with 5% carbon dioxide. After 24 hours of pre-incubation, the cells were treated with 1 μg / mL of LPS, and then treated with the test formula preparation diluted in a concentration gradient for 18 hours. The formula preparation was dissolved in water and further diluted into a concentration gradient, which were: 10 μg / mL, 20 μg / mL, 40 μg / mL, 80 μg / mL, 160 μg / mL. The amount of nitric oxide production was evaluated three times by adding 100 μL of Griess reagent (including reagent A and reagent B) to 100 μL of the cell supernatant of LPS-treated and LPS / compound-treated cells. After 5 minutes of incubation, the detection was carried out at a wavelength of 570 nm using a multi-label microplate reader, and the data was analyzed. Dexamethasone was used as a positive control, and its IC 50 = 12.3 μg / mL.

[0051] Test results

[0052] The inhibitory activity of nitric oxide production of the formula preparation was measured as: IC 50 = 78.4 μg / mL.

[0053] Test Example 2

[0054] Anti-pharyngitis activity experiment in animals

[0055] Test method

[0056] Establishment of a capsaicin-induced mouse pharyngitis model

[0057] 1) Modeling method:

[0058] Capsaicin was applied to the pharynx of mice. The pharyngeal tissue was taken for frozen section, HE staining, microscopic photography, and the thickness of the tissue epithelial layer was measured to evaluate the degree of inflammation.

[0059] Capsaicin for modeling: 6 mg / mL capsaicin + 10% ethanol + 10% Tween-80 + 80% normal saline

[0060] 2) Experimental group setting:

[0061] Solvent: 10% ethanol + 10% Tween-80 + 80% normal saline;

[0062] Positive drug group (topical application): 6 mg / mL capsaicin + 10% dexamethasone sodium phosphate injection (5 mg / mL) + 10% ethanol + 10% Tween-80 + 70% normal saline;

[0063] Test group (topical application): 6 mg / mL capsaicin + 10% ethanol + 10% Tween-80 + an appropriate amount of the test drug.

[0064] In vivo anti-inflammatory activity experimental method. The specific flow chart is as Figure 1 shown below:

[0065] 1) Preparation of experimental animals: Using the random grouping method, mice were caged, weighed, and recorded. They drank normal water (sterile water) and ate normally. After 4 days, they were weighed again and began to be grouped for water feeding. The test substance group was fed the plant extract at the target concentration, the model group and the control group continued to be fed sterile water until the end of the experiment. The positive control drug group was fed sterile water for the first three days and was changed to dexamethasone solution (1 mg / kg by body weight) on the last day. Each time during the experiment, the body weight of the mice, the amount of water and food intake, and any abnormal activities were recorded.

[0066] 2) Group setting and drug administration: The experiment was set up with a blank group, a model group, a positive control group (dexamethasone), and a drug administration group (including a low-dose formula preparation group with a concentration of 40 μg / mL and a high-dose formula preparation group with a concentration of 80 μg / mL), with 5 mice in each group. The mice were anesthetized by inhaling isoflurane. The mouse's mouth was pried open with an ophthalmic forceps, and the control group, the positive drug group, and the test group were respectively applied to the pharynx of the mice. Each application time was 10 seconds, repeated 3 times, with an interval of 30 minutes each time. The above operations were repeated for 4 days. 4 hours after the last application, the mice in each group were sacrificed by cervical dislocation.

[0067] 3) Processing of mouse pharyngeal tissue: The sacrificed mice were fixed to the dissection board, the two sides of the mouth were cut open to fully expose the pharynx. Using an ophthalmic curved forceps and a scalpel, the pharyngeal tissue was completely shaved off and placed in an EP tube, added with an appropriate amount of OCT (embedding agent), marked, and stored frozen.

[0068] 4) Frozen section: The cryostat was turned on one day in advance, the tissue was taken out and thawed, and embedded with the embedding agent. Pay attention to making the tissue stretch flat. Finally, a section block with a diameter of about 1.5 cm and a height of 1 cm was made, and the embedding was completed. Then the section was processed and the slide was pasted.

[0069] 5) HE staining: All the reagents required for staining were prepared in advance. According to the order of fixing solution A (30 - 60 seconds), pure water (30 seconds), fixing solution B (60 seconds), hematoxylin staining (10 minutes), water (rinsed for 5 seconds), 1% hydrochloric acid ethanol (5 seconds), water (10 minutes), eosin (5 minutes), 80%, 95%, 100% ethanol (2 seconds each), xylene (1 - 2 seconds), they were successively placed in the staining tanks, and finally taken out and dried.

[0070] 6) Microscopic reading of slides: Dip a small amount of neutral resin with a pipette onto the tissue, gently place the cover slip obliquely from one side to prevent the generation of air bubbles. After natural drying, place it under the microscope. First, observe at 4×10 magnification, then at 10×10 magnification, take pictures and record in sequence, save the pictures, select the target tissue segment, print it, measure the thickness of its epithelial tissue and conduct statistical induction to draw a conclusion.

[0071] Experimental results:

[0072] According to Figure 2 and the results in Table 1, it can be seen that compared with the model group, the epithelial layer thickness of the mice in the drug administration group decreased significantly, and the effect of the high-dose group was close to that of the positive drug dexamethasone. Through HE staining observation, the epithelial cell tissue distribution in the drug administration group was evenly distributed and tended to be normal, with low inflammatory reaction (as Figure 3 shown). The overall results indicate that the Dendrobium officinale and Phyllanthus emblica formula preparation in this invention patent has an obvious therapeutic effect on capsaicin-induced pharyngitis in mice.

[0073] Table 1 Statistical data on the therapeutic effect of the formula preparation on pharyngitis verified by the mouse pharyngitis model

[0074] Group Average thickness of pharyngeal tissue (mm) Blank group 6.21 Model group 11.28 Positive control group 6.56 High-dose group of formulated preparation 7.84 Low-dose group of formulated preparation 9.04

[0075] The above description of the present invention is intended to be illustrative and not restrictive. For those skilled in the art, various changes or modifications can be made to the embodiments described herein. These changes can be obtained without departing from the scope or spirit of the present invention.

Claims

1. A composition for treating pharyngolaryngitis, comprising: 30 - 40% Dendrobium officinale; 30 - 40% Phyllanthus emblica; and the balance of honey.

2. The composition according to claim 1, comprising: 35% Dendrobium officinale; 35% Phyllanthus emblica; and the balance of honey.

3. The composition according to claim 1, wherein: The Dendrobium officinale is freeze-dried and then ultrafinely pulverized to form Dendrobium officinale ultrafine powder with a particle size of 10 ± 5 μm.

4. The composition according to claim 1, wherein: The Phyllanthus emblica is pitted, freeze-dried, and then ultrafinely pulverized to form Phyllanthus emblica ultrafine powder with a particle size of 10 ± 5 μm.

5. A preparation method of the composition for treating pharyngolaryngitis according to any one of claims 1 to 4 above, comprising: Mixing the Dendrobium officinale ultrafine powder, Phyllanthus emblica ultrafine powder and honey to obtain the composition.

6. A drug for treating pharyngolaryngitis, comprising: Mixing the composition according to any one of claims 1 to 4 with pharmaceutically common excipients to obtain a drug for treating pharyngolaryngitis.

7. The drug according to claim 6, wherein: The drug includes but is not limited to: Tablets, capsules, pills, liquid preparations.

8. An application of the composition according to any one of claims 1 to 4 in the treatment of pharyngolaryngitis.

9. An application of the drug according to claim 6 or 7 in the treatment of pharyngolaryngitis.

Images